Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 5 (May)

1. An unusual case of weight loss in a patient with refractory rheumatoid arthritis.
   Age Ageing, 34(3): 305-6. [Abstract] [Full-text]
2. Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review.
   Gynecol Oncol, 97(2): 700-3. [Abstract] [Full-text]
3. Test-retest of self-reported exposure to artificial tanning devices, self-tanning creams, and sun sensitivity showed consistency.
   J Clin Epidemiol, 58(4): 430-2. [Abstract] [Full-text]
4. Geographic variation in sentinel node adaptation by practicing surgeons in Oregon.
   Am J Surg, 189(5): 616-9; discussion 619-20. [Abstract] [Full-text]
5. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells.
   FEBS Lett, 579(12): 2722-6. [Abstract] [Full-text]
6. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system.
   Ann Surg Oncol, 12(4): 282-8. [Abstract] [Full-text]
7. Multiplex reverse transcription-polymerase chain reaction combined with on-chip electrophoresis as a rapid screening tool for candidate gene sets.
   Electrophoresis, 26(9): 1687-91. [Abstract] [Full-text]
8. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
   Cancer Res, 65(9): 3937-41. [Abstract] [Full-text]
9. Cancer immunotherapy based on killing of Salmonella-infected tumor cells.
   Cancer Res, 65(9): 3920-7. [Abstract] [Full-text]
10. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity.
    Cancer Res, 65(9): 3586-95. [Abstract] [Full-text]
11. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
    Clin Cancer Res, 11(9): 3402-9. [Abstract] [Full-text]
12. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress.
    Clin Cancer Res, 11(9): 3175-83. [Abstract] [Full-text]
13. Osteogenic melanoma.
    APMIS, 113(4): 296-300. [Abstract] [Full-text]
14. Libraries enriched for alternatively spliced exons reveal splicing patterns in melanocytes and melanomas.
    Nat Methods, 1(3): 233-9. [Abstract] [Full-text]
15. Role of epidermal growth factor receptor signaling in RAS-driven melanoma.
    Mol Cell Biol, 25(10): 4176-88. [Abstract] [Full-text]
16. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
    Int J Dermatol, 44(5): 428-34. [Abstract] [Full-text]
17. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2.
    Cancer Biother Radiopharm, 20(2): 151-4. [Abstract] [Full-text]
18. Skeletrophin, a novel RING molecule controlled by the chromatin remodeling complex, is downregulated in malignant melanoma.
    DNA Cell Biol, 24(5): 339-44. [Abstract] [Full-text]
19. Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down-regulation of transferrin receptor dependent iron uptake.
    J Cell Physiol, 204(1): 192-7. [Abstract] [Full-text]
20. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
    Hum Gene Ther, 16(4): 457-72. [Abstract] [Full-text]
21. Early CT-scan for chronic lacrimal duct symptoms - case report of a malignant melanoma of the lacrimal sac and review of the literature.
    J Craniomaxillofac Surg, 33(3): 201-4. [Abstract] [Full-text]
22. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
    Ophthalmology, 112(5): 834-40. [Abstract] [Full-text]
23. Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis.
    Arch Ophthalmol, 123(5): 654-61. [Abstract] [Full-text]
24. Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25.
    Arch Ophthalmol, 123(5): 601-4. [Abstract] [Full-text]
25. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.
    J Gene Med, 7(5): 613-20. [Abstract] [Full-text]
26. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability.
    J Gene Med, 7(5): 604-12. [Abstract] [Full-text]
27. 5-aminolaevulinic acid photodynamic therapy in a transgenic mouse model of skin melanoma.
    Exp Dermatol, 14(6): 429-37. [Abstract] [Full-text]
28. Utility of the Wood's light: five cases from a pigmented lesion clinic.
    Br J Dermatol, 152(5): 1039-44. [Abstract] [Full-text]
29. Has mortality from malignant melanoma stopped rising in Spain? Analysis of trends between 1975 and 2001.
    Br J Dermatol, 152(5): 997-1000. [Abstract] [Full-text]
30. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
    Br J Dermatol, 152(5): 948-53. [Abstract] [Full-text]
31. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV.
    Br J Dermatol, 152(5): 931-8. [Abstract] [Full-text]
32. Microarray analysis of phosphatase gene expression in human melanoma.
    Br J Dermatol, 152(5): 925-30. [Abstract] [Full-text]
33. Presence of high-risk mucosal human papillomavirus genotypes in primary melanoma and in acquired dysplastic melanocytic naevi.
    Br J Dermatol, 152(5): 909-14. [Abstract] [Full-text]
34. Subepidermal cleft formation as a diagnostic marker for cutaneous malignant melanoma.
    Hum Pathol, 36(4): 412-5. [Abstract] [Full-text]
35. Multi-spectral image analysis and classification of melanoma using fuzzy membership based partitions.
    Comput Med Imaging Graph, 29(4): 287-96. [Abstract] [Full-text]
36. RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
    Oncogene, 24(21): 3535-40. [Abstract] [Full-text]
37. Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma.
    J Lipid Res, 46(6): 1278-84. [Abstract] [Full-text]
38. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Oncogene, 24(21): 3459-71. [Abstract] [Full-text]
39. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis.
    Pigment Cell Res, 18(3): 196-202. [Abstract] [Full-text]
40. Histone deacetylase inhibitors and malignant melanoma.
    Pigment Cell Res, 18(3): 160-6. [Abstract] [Full-text]
41. Adhesion, migration and communication in melanocytes and melanoma.
    Pigment Cell Res, 18(3): 150-9. [Abstract] [Full-text]
42. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene.
    Cancer Gene Ther, 12(6): 528-39. [Abstract] [Full-text]
43. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination.
    Cancer Gene Ther, 12(6): 579-91. [Abstract] [Full-text]
44. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Cancer Gene Ther, 12(6): 516-27. [Abstract] [Full-text]
45. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
    Cancer Gene Ther, 12(6): 552-9. [Abstract] [Full-text]
46. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis.
    Clin Cancer Res, 11(10): 3925-9. [Abstract] [Full-text]
47. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma.
    Clin Cancer Res, 11(10): 3609-13. [Abstract] [Full-text]
48. A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells.
    J Biol Chem, 280(20): 19516-26. [Abstract] [Full-text]
49. Soluble branched (1,4)-beta-D-glucans from Acetobacter species enhance antitumor activities against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response.
    Int J Cancer, 115(5): 769-76. [Abstract] [Full-text]
50. Phenotypic profiling of engineered mouse melanomas with manipulated histamine production identifies histamine H2 receptor and rho-C as histamine-regulated melanoma progression markers.
    Cancer Res, 65(10): 4458-66. [Abstract] [Full-text]
51. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.
    Cancer Res, 65(10): 4320-33. [Abstract] [Full-text]
52. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines.
    Cancer Res, 65(10): 4172-80. [Abstract] [Full-text]
53. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis.
    Cancer Res, 65(10): 4134-46. [Abstract] [Full-text]
54. E2F-dependent repression of topoisomerase II regulates heterochromatin formation and apoptosis in cells with melanoma-prone mutation.
    Cancer Res, 65(10): 4067-77. [Abstract] [Full-text]
55. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.
    Cancer Res, 65(10): 4005-11. [Abstract] [Full-text]
56. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
    Clin Chem Lab Med, 43(5): 557-63. [Abstract] [Full-text]
57. Near-infrared optical imaging of B16 melanoma cells via low-density lipoprotein-mediated uptake and delivery of high emission dipole strength tris[(porphinato)zinc(II)] fluorophores.
    Bioconjug Chem, 16(3): 542-50. [Abstract] [Full-text]
58. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    Br J Cancer, 92(10): 1881-91. [Abstract] [Full-text]
59. Pigmentary characteristics and moles in relation to melanoma risk.
    Int J Cancer, 116(1): 144-9. [Abstract] [Full-text]
60. Parallel expression of alphaIIbbeta3 and alphavbeta3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype.
    Int J Cancer, 116(1): 27-35. [Abstract] [Full-text]
61. Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma.
    Int J Dev Biol, 49(2): 173-80. [Abstract] [Full-text]
62. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
    Ann Oncol, 16(6): 950-7. [Abstract] [Full-text]
63. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.
    Eur J Cancer, 41(8): 1213-22. [Abstract] [Full-text]
64. Photothermal sensitisation as a novel therapeutic approach for tumours: studies at the cellular and animal level.
    Eur J Cancer, 41(8): 1203-12. [Abstract] [Full-text]
65. P2Y purinergic receptors regulate the growth of human melanomas.
    Cancer Lett, 224(1): 81-91. [Abstract] [Full-text]
66. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
    Ann Surg Oncol, 12(5): 381-90. [Abstract] [Full-text]
67. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine.
    Int Immunopharmacol, 5(7): 1343-52. [Abstract] [Full-text]
68. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.
    Int Immunopharmacol, 5(7): 1205-12. [Abstract] [Full-text]
69. Intratumor heterogeneity in blood perfusion in orthotopic human melanoma xenografts assessed by dynamic contrast-enhanced magnetic resonance imaging.
    J Magn Reson Imaging, 21(6): 792-800. [Abstract] [Full-text]
70. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
    Clin Chem, 51(6): 981-8. [Abstract] [Full-text]
71. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
    J Clin Pathol, 58(6): 640-4. [Abstract] [Full-text]
72. Childhood subungual melanoma in situ in diffuse nail melanosis beginning as expanding longitudinal melanonychia.
    Pediatr Dermatol, 22(3): 210-2. [Abstract] [Full-text]
73. Dermoscopy of an acral congenital melanocytic nevus.
    Pediatr Dermatol, 22(3): 188-91. [Abstract] [Full-text]
74. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
    Cancer Immunol Immunother, 54(7): 703-12. [Abstract] [Full-text]
75. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
    Cancer Immunol Immunother, 54(7): 677-84. [Abstract] [Full-text]
76. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy.
    Br J Ophthalmol, 89(6): 730-8. [Abstract] [Full-text]
77. Recruiting donors for autopsy based cancer research.
    J Med Ethics, 31(6): 360-1. [Abstract] [Full-text]
78. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions.
    Am J Clin Pathol, 124(1): 37-48. [Abstract] [Full-text]
79. Experimental model of pulmonary metastasis treatment with IFNalpha.
    Cancer Lett, 225(1): 75-83. [Abstract] [Full-text]
80. Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.
    Biochem Biophys Res Commun, 332(3): 873-9. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.